Skip to main content
Caplin Point Laboratories Ltd. logo

Caplin Point Laboratories Ltd. — Investor Relations & Filings

Ticker · CAPLIPOINT ISIN · INE475E01026 LEI · 33580043U3LXMROY5J69 BSE.NS Manufacturing
Open in API
Filings indexed 701 across all filing types
Latest filing 2026-05-14 Report Publication Anno…
Country IN India
Listing BSE.NS CAPLIPOINT

About Caplin Point Laboratories Ltd.

https://www.caplinpoint.net

Caplin Point Laboratories Ltd. is a pharmaceutical organization focused on the development, manufacturing, and marketing of finished dosage forms. Its extensive product portfolio encompasses tablets, capsules, injections, liquid orals, and softgel capsules across diverse therapeutic categories. The company utilizes a vertically integrated business model, overseeing the complete value chain from research and development to final distribution. Caplin Point maintains a significant market presence in Latin America and Francophone Africa, supported by a specialized end-to-end logistics and supply chain network. Furthermore, through its subsidiary Caplin Steriles, the company has established a footprint in regulated markets, specializing in sterile injectables and ophthalmic products. Its manufacturing infrastructure is designed to meet global regulatory requirements, including certifications from the US FDA and EU GMP.

Recent filings

Filing Released Lang Actions
Earnings call for Q4(2025-26)
Report Publication Announcement Classification · 85% confidence The document is a short notice to stock exchanges that the audio recording of the Q4/FY2025-26 earnings call has been made available on the company website. It does not contain the earnings data itself, nor the transcript, but simply announces the publication of the recording. Under the “Menu vs Meal” rule, this is an announcement of report availability rather than a full report or transcript. Therefore, it fits “Report Publication Announcement” (RPA).
2026-05-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Report Publication Announcement Classification · 85% confidence The document is a short corporate announcement to stock exchanges informing investors that the audio recording of the Q4 FY2025-26 earnings call has been made available on the company website. It contains no financial statements or substantive data, and simply notifies about the publication of an audio report rather than delivering the report itself. Under our definitions, this is a Report Publication Announcement (RPA).
2026-05-14 English
Press Release
Regulatory Filings Classification · 85% confidence The document is a press release submitted to the BSE and NSE announcing the receipt of US FDA approval for a subsidiary’s ANDA. It is neither a financial report (10-K, IR, etc.) nor an earnings release, management discussion, or regulatory certification. It does not announce a report publication but rather a corporate event. As there is no specific category for product approvals, this falls under the fallback “General regulatory announcements” category (RNS).
2026-05-14 English
Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA, for Foscarnet Sodium Injection
Regulatory Filings Classification · 87% confidence The document is a press release announcing regulatory approval (USFDA approval for an ANDA product) filed with stock exchanges (BSE and NSE). It is not a financial report, earnings release, or other specific category but rather a general regulatory announcement to exchanges. There is no substantive financial data, only an announcement of approval and company background. This fits the fallback category ‘Regulatory Filings (RNS)’ for general announcements and compliance documents.
2026-05-14 English
The Board at its meeting held today, May 14, 2026, had declared Interim Dividend of INR.4.00 (200%) per equity share for the FY 2025-26 and fixed the Record date as May 30, 2026.
Audit Report / Information Classification · 86% confidence The filing is a detailed Independent Auditor’s Report on the audited standalone and consolidated financial results of the company for the year ended March 31, 2026, complete with audit opinion, basis for opinion, management’s responsibilities, and other standard audit report sections. It is not a full annual report (10-K), nor merely a notice of report publication, but rather the standalone audit report itself. This matches the “Audit Report / Information” category (AR).
2026-05-14 English
Record Date
Audit Report / Information Classification · 82% confidence The document is an official SEBI LODR filing containing the ‘Outcome of Board Meeting’ letter and, as Annexure-1, the full Independent Auditor’s Report on the audited consolidated quarterly and annual financial results for the year ended March 31, 2026. The core of the text is the standalone audit report (opinion, basis, responsibilities), which fits the definition of a standalone audit report (Code: AR).
2026-05-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.